Kazia to Collaborate with Pacific Pediatric Neuro-Oncology Consortium (PNOC) for New Paxalisib Combination Study in DIPG-PR Newswire APAC

SYDNEY, Dec. 10, 2020 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce that it has executed a Letter of Intent with the Pacific Pediatric Neuro-Oncology Consortium (PNOC) to launch a clinical trial of multiple therapies, including Kazia's...

Read more: Kazia to Collaborate with Pacific Pediatric Neuro-Oncology Consortium (PNOC) for New Paxalisib Combi...

More Articles …

  1. Bruce Rock Engineering Unveils New Super Quad with SSAB's New Wear Steel-PR Newswire APAC
  2. ActLight expands its IP portfolio with the launch of the Stand-Alone Dynamic PhotoDiode
  3. A plan to address fossil fuels is key for the Climate Ambition Summit
  4. Top-line Final Data from Cantrixil Phase I Study Confirms Prior Positive Efficacy and Safety Signals
  5. Thunderhead expands APAC footprint with hire of industry thought leader Aarron Spinley, VP ANZ
  6. Welsh Developments ACTC Pty Ltd Announces Offering of AUD 142,726,327 Senior Secured Loan Note Offer
  7. Adyen to partner with Hungry Jack's to improve its customer service with payment-led updates
  8. Trineo Joins B Corp™ Community; Pledges To Use Business As Force For Good
  9. Over 65 speakers across 8 countries address critical themes of 'Readiness', 'Security' and 'Transparency' at URAP2 conference
  10. Novotech Health Holdings Announces Appointment of Anand Tharmaratnam as Chairman